Tag: Blood Disorders
FDA Approves First Treatment for Congenital Thrombotic Thrombocytopenic Purpura
The genetically engineered protein product is safe, effective for the rare inherited blood clotting disorder
Tolerable Treatments Lacking for Higher-Risk Myelodysplastic Syndromes
61 percent of 200 patients with higher-risk MDS were subsequently hospitalized within six months of diagnosis
Efgartigimod Efficacious, Safe for Primary Immune Thrombocytopenia
More patients receiving efgartigimod reached primary end point of sustained platelet count response
Risk for Intracerebral Hemorrhage May Be Transmissible Via Blood Transfusion
Risk was increased for those receiving transfusion from donors who later developed multiple spontaneous intracerebral hemorrhages
Red Cross Appeals for Donors During National Blood Shortage
Back-to-back climate-related disasters have hampered blood collection efforts, and a summer shortfall has made the shortage worse
Concizumab May Be Effective Prophylaxis for Hemophilia A or B With Inhibitors
Overall median annualized bleeding rate was 0 with concizumab
Prognostic Factors ID’d for Stage IIIb AL Amyloidosis
Symptom onset to diagnosis longer than six months, bone marrow plasmacytosis ≥10 percent associated with shorter overall survival
Misdiagnosis Common for Suspected Myelodysplastic Neoplasms
About one-third of cases were reclassified following central review; receipt of inappropriate meds reported in 7 percent of misdiagnosed cases
International Prognostic Scoring System-Molecular Changes Clinical Management
For nearly half of patients with myelodysplastic syndromes, results could change clinical care
Tranexamic Acid Does Not Up Functional Outcome After Major Trauma
No improvement seen in favorable functional outcome at six months, but reduced risk of death at 28 days after injury
